Syndax Pharmaceuticals SNDX
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 66th percentile, 5-year average 5.1x
Near the bottom of its 5-year range · 1st percentile, 5-year average 12.4x
#5264 of 5335 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 0th percentile, 5-year average 44.7x
#3128 of 5159 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | -49.48 | – | 12.36 | 1% (cheaper than usual) | #5264 of 5335 (1 = cheapest) |
| PE | -3.99 | -6.12 | 5.07 | 66% (pricier than usual) | – |
| PS | 2.94 | 2.10 | 44.68 | 0% (cheaper than usual) | #3128 of 5159 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on SNDX.
Sign in to join the discussion.